Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

GvHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR.

Blood. 2015 Aug 11. pii: blood-2015-03-634691. [Epub ahead of print]

PMID:
26265697
2.

Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Modiano JF, Lindborg BA, McElmurry RT, Lewellen M, Forster CL, Zamora EA, Schaack J, Bellgrau D, O'Brien TD, Tolar J.

Cancer Immunol Immunother. 2015 Aug 7. [Epub ahead of print]

PMID:
26250807
3.

From Mesoderm to Mesodermatology: Bone Marrow Mesenchymal Cells Heal Skin Wounds.

Tolarova M, Tolar J.

Mol Ther. 2015 Aug;23(8):1283-4. doi: 10.1038/mt.2015.84. No abstract available.

PMID:
26227251
4.

Second allogeneic hematopoietic cell transplantation for graft failure: Poor outcomes for neutropenic graft failure.

Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, Brunstein C, Wagner JE, Verneris MR, Weisdorf D.

Am J Hematol. 2015 Jul 6. doi: 10.1002/ajh.24111. [Epub ahead of print]

PMID:
26149534
5.

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Perdoni C, Osborn MJ, Tolar J.

Transl Res. 2015 May 27. pii: S1931-5244(15)00175-9. doi: 10.1016/j.trsl.2015.05.008. [Epub ahead of print] Review.

PMID:
26073463
6.

Sickle cell and silent spleen.

Tolar J.

Blood. 2015 Apr 23;125(17):2589-90. doi: 10.1182/blood-2015-03-633933.

PMID:
25907900
7.

Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.

Petrof G, Lwin SM, Martinez-Queipo M, Abdul-Wahab A, Tso S, Mellerio JE, Slaper-Cortenbach I, Boelens JJ, Tolar J, Veys P, Ofuya M, Peacock JL, Martinez AE, McGrath JA.

J Invest Dermatol. 2015 Sep;135(9):2319-21. doi: 10.1038/jid.2015.158. Epub 2015 Apr 23. No abstract available.

PMID:
25905587
8.

From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Webber BR, Tolar J.

Mol Ther. 2015 Jun;23(6):987-92. doi: 10.1038/mt.2015.47. Epub 2015 Mar 24. Review.

PMID:
25803200
9.

Placenta-based therapies for the treatment of epidermolysis bullosa.

Nevala-Plagemann C, Lee C, Tolar J.

Cytotherapy. 2015 Jun;17(6):786-95. doi: 10.1016/j.jcyt.2015.03.006. Epub 2015 Mar 18. Review.

PMID:
25795271
10.

The three-body problem of therapy with induced pluripotent stem cells.

Tolar J, McGrath JA.

Genome Med. 2015 Feb 20;7(1):15. doi: 10.1186/s13073-015-0141-7. eCollection 2015.

11.

Alternative donor transplant of benign primary hematologic disorders.

Tolar J, Sodani P, Symons H.

Bone Marrow Transplant. 2015 May;50(5):619-27. doi: 10.1038/bmt.2015.1. Epub 2015 Feb 9. Review.

12.

A living band-aid for epidermolysis bullosa.

Tolar J, Tolar M.

Blood Transfus. 2015 Jan;13(1):1-2. doi: 10.2450/2014.0289-14. No abstract available.

13.

Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.

Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK, Tolar J, Allewelt H, Jones SA, Parini R, Renard M, Bordon V, Wulffraat NM, de Koning TJ, Shapiro EG, Kurtzberg J, Boelens JJ.

Blood. 2015 Mar 26;125(13):2164-72. doi: 10.1182/blood-2014-11-608075. Epub 2015 Jan 26.

PMID:
25624320
14.

A biologic Velcro patch.

Tolar J, Wagner JE.

N Engl J Med. 2015 Jan 22;372(4):382-4. doi: 10.1056/NEJMcibr1414709. No abstract available.

PMID:
25607432
15.

Fanconi anemia gene editing by the CRISPR/Cas9 system.

Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J.

Hum Gene Ther. 2015 Feb;26(2):114-26. doi: 10.1089/hum.2014.111.

PMID:
25545896
16.

The individual (single patient) IND for inborn errors of metabolism.

Dickson PI, Tolar J.

Mol Genet Metab. 2014 Oct 13. pii: S1096-7192(14)00312-6. doi: 10.1016/j.ymgme.2014.10.003. [Epub ahead of print]

PMID:
25456747
17.

Peripheral neuro-immune pathology in recessive dystrophic epidermolysis bullosa.

Mack MR, Wendelschafer-Crabb G, McAdams BD, Hordinsky MK, Kennedy WR, Tolar J.

J Invest Dermatol. 2015 Apr;135(4):1193-7. doi: 10.1038/jid.2014.500. Epub 2014 Nov 14. No abstract available.

PMID:
25431850
18.

Derivation and high engraftment of patient-specific cardiomyocyte sheet using induced pluripotent stem cells generated from adult cardiac fibroblast.

Zhang L, Guo J, Zhang P, Xiong Q, Wu SC, Xia L, Roy SS, Tolar J, O'Connell TD, Kyba M, Liao K, Zhang J.

Circ Heart Fail. 2015 Jan;8(1):156-66. doi: 10.1161/CIRCHEARTFAILURE.114.001317. Epub 2014 Nov 24.

PMID:
25420485
19.

Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa.

Perdoni C, McGrath JA, Tolar J.

Stem Cell Res Ther. 2014 Nov 6;5(6):121. doi: 10.1186/scrt511.

20.

An exploratory analysis of mitochondrial haplotypes and allogeneic hematopoietic cell transplantation outcomes.

Ross JA, Tolar J, Spector LG, DeFor T, Lund TC, Weisdorf DJ, Langer E, Hooten AJ, Thyagarajan B, Gleason MK, Wagner JE, Robien K, Verneris MR.

Biol Blood Marrow Transplant. 2015 Jan;21(1):81-8. doi: 10.1016/j.bbmt.2014.09.023. Epub 2014 Oct 6.

PMID:
25300867
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk